<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00507715</url>
  </required_header>
  <id_info>
    <org_study_id>PLAN-EC-LDOPA-FI</org_study_id>
    <secondary_id>EudraCT number:2006-000491-33</secondary_id>
    <nct_id>NCT00507715</nct_id>
  </id_info>
  <brief_title>Study of the Modification of the Pharmacokinetic Profile of Levodopa by the Fiber Plantago Ovata Husk</brief_title>
  <official_title>Clinical Trial to Study the Modification of the Pharmacokinetic Profile of Levodopa by the Fiber Plantago Ovata Husk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rottapharm Spain</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rottapharm Spain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to study the effect of the association levodopa/carbidopa with
      plantago ovata husk in Parkinson´s disease patients of recent diagnostic, that are being
      treated with levodopa/carbidopa.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although the treatment with l-dopa is the election treatment for Parkinson´s disease, a high
      number of patients develop motor complications, including, fluctuations and dyscinesia after
      some years of treatment.

      The origin of the fluctuations is not well established, but it could be attributed, al least
      partially, a pharmacokinetics factors. So that, it could improve the answer and reduce the
      adverse reaction if we reach more stable levels of L-dopa in the circulation. The first
      experimental studies in animals showed that Plantago ovata husk has an influence in the
      pharmacokinetics parameters of L-dopa, obtaining more stable levels.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To study how the fiber Plantago ovata husk modifies the pharmacokinetics parameters of the absorption and elimination of L-dopa.</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate if the treatment with Plantago ovata husk modifies the biochemical parameters as total cholesterol, HDL y LDL, glycaemia, etc.</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Parkinson's Disease, Idiopathic</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plantago ovata husk</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>hemicellulose crystalline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plantago ovata husk</intervention_name>
    <description>5 g of effervescent powder (3.5 g pf plantago ovata husk) t.i.d. during 14 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>hemicellulose crystalline</intervention_name>
    <description>5g effervescent powder t.id. during 14 days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with diagnostic of idiopathic Parkinson disease, with well controlled
             symptomatology with administration of l-dopa/carbidopa.

          -  At least 3 months of treatment continued of levodopa.

          -  Patients that give the their consent to participate in the study.

        Exclusion Criteria:

          -  Patients with diagnostic of idiopathic Parkinson disease, with bad controlled
             symptomatology with administration of l-dopa/carbidopa.

          -  Patients with allergic predisposition to Plantago ovata husk or other
             contraindications for its use.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sierra Matilde, Ph, phD</last_name>
    <role>Study Chair</role>
    <affiliation>Departamento de Ciencias Biomédicas de la Facultad de Veterinaria de la Universidad de León, León (Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carriedo Demetrio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de León, León (Spain)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de León</name>
      <address>
        <city>Leon</city>
        <state>León</state>
        <zip>24071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2007</study_first_submitted>
  <study_first_submitted_qc>July 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2007</study_first_posted>
  <last_update_submitted>July 25, 2007</last_update_submitted>
  <last_update_submitted_qc>July 25, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2007</last_update_posted>
  <keyword>Parkinson's Disease, Idiopathic</keyword>
  <keyword>l-dopa levels</keyword>
  <keyword>plantago ovata husk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

